Allison F. O’Neill, MD completed undergraduate training at Yale University, medical training at Albert Einstein University, residency training at Boston Children’s Hospital and pediatric hematology/oncology training at Dana-Farber and Boston Children’s Hospital Cancer and Blood Disorders Center. Her current appointment is with Dana-Farber Cancer Institute within Harvard University in the capacity of Assistant Professor of Pediatrics.

Dr. O’Neill is the Clinical Director of the Pediatric Solid Tumor Program and Medical Director of the Liver Tumor Center of Excellence at Dana-Farber Cancer Institute and Boston Children’s Hospital. In her role as Director of the Solid Tumor Program, her overarching responsibilities include guiding clinical research initiatives in concert with the experimental therapeutics division and cultivating a programmatic mission surrounding multidisciplinary clinics, visibility in the rare tumor space, and expanding initiatives in immunotherapy. The Liver Tumor Center of Excellence collaboratively unites individuals of a broad multidisciplinary expertise to deliver care to children with these exceptionally rare tumors. At the national level, Dr. O’Neill is the Chair of the Children’s Oncology Group Liver Tumor Committee and co-authored the HCC arm of the current International Hepatoblastoma study, AHEP1531/PHITT. Dr. O’Neill has designed two prospective studies for pediatric patients with relapsed HCC, a multi-institutional protocol studying the efficacy of checkpoint inhibition and a sponsor-initiated single-institute trial studying an engineered T-cell targeting AFP.